Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
LOS ANGELES, March 27, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
-
NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for...
-
Dublin, March 27, 2026 (GLOBE NEWSWIRE) -- The "Bispecific T-Cell Engagers Market Report 2026" has been added to ResearchAndMarkets.com's offering. The bispecific T-cell engagers market is...
-
Investors who lost money in COTY after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
-
Dublin, March 27, 2026 (GLOBE NEWSWIRE) -- The "Australia mRNA Therapeutics Market: Industry Trends and Global Forecasts, till 2035 - Distribution by Application Area (COVID-19 and Other...
-
Notice of ordinary and extraordinary shareholders’ meetings Umicore invites its shareholders to participate in the ordinary and extraordinary shareholders’ meetings, which will be held on Thursday,...
-
NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of monday.com Ltd. (NASDAQ: MNDY). Shareholders who purchased shares of MNDY during the...
-
Dublin, March 27, 2026 (GLOBE NEWSWIRE) -- The "CAR T-Cell Therapy Market by Product, Target, Indication, Demographic, Region, Competitive Landscape - Global Forecast to 2031" has been added to ...
-
Volta Finance Limited (VTA / VTAS)February 2026 monthly reportNOT FOR RELEASE, DISTRIBUTION, OR PUBLICATION, IN WHOLE OR PART, IN OR INTO THE UNITED STATES Guernsey, March 27th, 2026 BNPP AM has...
-
Poster #76954 highlights QTORIN™ rapamycin’s single phase anhydrous gel formulation designed to optimize dermal bioavailability of rapamycin for mTOR-driven skin diseases while overcoming the...